160 related articles for article (PubMed ID: 36249060)
1. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy.
Xu S; Sak A; Niedermaier B; Erol YB; Groneberg M; Mladenov E; Kang M; Iliakis G; Stuschke M
Front Oncol; 2022; 12():999626. PubMed ID: 36249060
[TBL] [Abstract][Full Text] [Related]
2. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
3. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of BRD4 and ATR/WEE1 pathways exploits
Kinose Y; Xu H; Kim H; Kumar S; Shan X; George E; Wang X; Medvedev S; Ferman B; Gitto SB; Whicker M; D'Andrea K; Wubbenhorst B; Hallberg D; O'Connor M; Schwartz LE; Hwang WT; Nathanson KL; Mills GB; Velculescu VE; Wang TL; Brown EJ; Drapkin R; Simpkins F
Res Sq; 2023 Sep; ():. PubMed ID: 37841875
[No Abstract] [Full Text] [Related]
5. Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Park Y; Chui MH; Suryo Rahmanto Y; Yu ZC; Shamanna RA; Bellani MA; Gaillard S; Ayhan A; Viswanathan A; Seidman MM; Franco S; Leung AKL; Bohr VA; Shih IM; Wang TL
Clin Cancer Res; 2019 Sep; 25(18):5584-5594. PubMed ID: 31196855
[TBL] [Abstract][Full Text] [Related]
6. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Williamson CT; Miller R; Pemberton HN; Jones SE; Campbell J; Konde A; Badham N; Rafiq R; Brough R; Gulati A; Ryan CJ; Francis J; Vermulen PB; Reynolds AR; Reaper PM; Pollard JR; Ashworth A; Lord CJ
Nat Commun; 2016 Dec; 7():13837. PubMed ID: 27958275
[TBL] [Abstract][Full Text] [Related]
7. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
8. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
Mohni KN; Thompson PS; Luzwick JW; Glick GG; Pendleton CS; Lehmann BD; Pietenpol JA; Cortez D
PLoS One; 2015; 10(5):e0125482. PubMed ID: 25965342
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
Yakovlev VA; Sullivan SA; Fields EC; Temkin SM
Front Oncol; 2023; 13():1124147. PubMed ID: 36910637
[TBL] [Abstract][Full Text] [Related]
10. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy.
Wang M; Ran X; Leung W; Kawale A; Saxena S; Ouyang J; Patel PS; Dong Y; Yin T; Shu J; Manguso RT; Lan L; Wang XF; Lawrence MS; Zou L
Genes Dev; 2023 Oct; 37(19-20):929-943. PubMed ID: 37932012
[TBL] [Abstract][Full Text] [Related]
11. Targeting ATR in cancer medicine.
Sundar R; Brown J; Ingles Russo A; Yap TA
Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
[TBL] [Abstract][Full Text] [Related]
12. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
13. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
14.
Kurz L; Miklyaeva A; Skowron MA; Overbeck N; Poschmann G; Becker T; Eul K; Kurz T; Schönberger S; Calaminus G; Stühler K; Dykhuizen E; Albers P; Nettersheim D
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272809
[TBL] [Abstract][Full Text] [Related]
15. Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells.
Wu C; Lyu J; Yang EJ; Liu Y; Zhang B; Shim JS
Nat Commun; 2018 Aug; 9(1):3212. PubMed ID: 30097580
[TBL] [Abstract][Full Text] [Related]
16. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [
Carlucci G; Carney B; Sadique A; Vansteene A; Tang J; Reiner T
Nucl Med Biol; 2017 May; 48():9-15. PubMed ID: 28157626
[TBL] [Abstract][Full Text] [Related]
18. Proficiency in homologous recombination repair is prerequisite for activation of G
Soni A; Mladenov E; Iliakis G
DNA Repair (Amst); 2021 May; 101():103076. PubMed ID: 33640756
[TBL] [Abstract][Full Text] [Related]
19. ATR inhibition reverses the resistance of homologous recombination deficient MGMT
El Touny LH; Hose C; Connelly J; Harris E; Monks A; Dull AB; Wilsker DF; Hollingshead MG; Gottholm-Ahalt M; Alcoser SY; Mullendore ME; Parchment RE; Doroshow JH; Teicher BA; Rapisarda A
Oncotarget; 2021 Oct; 12(21):2114-2130. PubMed ID: 34676045
[TBL] [Abstract][Full Text] [Related]
20. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
